Secured Rights Issue 2018

Investors
<picture><source type="image/webp" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/18e05/Image-1.webp 740w,/static/2cf241996b0d6d9b54351b76891640b8/81bef/Image-1.webp 1480w,/static/2cf241996b0d6d9b54351b76891640b8/2d0b8/Image-1.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/bbd3f/Image-1.jpg 740w,/static/2cf241996b0d6d9b54351b76891640b8/087e6/Image-1.jpg 1480w,/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg 2960w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate Governance
Articles of Association
General meeting
Board of Directors
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Scientific advisory board
Archived transactions
Shareholder & stock info
Share monitor
Shareholders
Convertible bonds
Analyst coverage
Financial reports
Financial calendar
Secured Rights Issue 2018On this page, you will find all relevant information that are published in connection with Immunicums’ proposed Rights Issue.
Press release
Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue23 November 2018

Download PDF

Finn prospekt och anmälningssedlar längre ned på sidan
Press release
Immunicum AB (publ) Clarifies Information Regarding Directed Issue16 October 2018

Download PDF
Press release
Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel – a New and Innovative Cancer Immunotherapy16 October 2018

Download PDF
Press release
Notice of extraordinary general meeting in Immunicum AB (publ)16 October 2018

Download PDF
Prospectus23 November 2018

Download PDF (only Swedish)
Frequently Asked Questions – Financing2 November 2018

Download PDF
Extraordinary general meeting 201816 October 2018

Board resolution on directed share issue

Board proposal for resolution on directed share issue

Board resolution on rights issue

Board proposal for resolution on rights issue

Board’s report

Auditor’s statement (in Swedish)

Power of Attorney form

Investors

Secured Rights Issue 2018

Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue

Immunicum AB (publ) Clarifies Information Regarding Directed Issue

Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel – a New and Innovative Cancer Immunotherapy

Notice of extraordinary general meeting in Immunicum AB (publ)

Prospectus

Frequently Asked Questions – Financing

Extraordinary general meeting 2018

Keep up to date